GenomOncology Launches New Version of Pathology Workbench Tool

By StartUp City | Tuesday, October 20, 2020

The latest launch of GenomOncology's Pathology Workbench allows for the parallel processing of samples via the annotation pipeline, improving sample annotation time by 80 percent.

FREMONT, CA: GenomOncology declared the launch of its newest version of the GenomOncology (GO) Pathology Workbench solution, which is optimized for higher sample throughput, larger panels, and the interpretation of copy numbers and structural variants by Next Generation Sequencing (NGS).

GenomOncology's Pathology Workbench is an end-to-end, customizable solution that streamlines quality control review as well as clinical interpretation for NGS tests. The tool is built to identify matched potential clinical trials, annotate detected variants and therapies, and lead to a customizable report that can be easily integrated into other systems. The GO Pathology Workbench covers multiple annotation sets and curated content to help sample analysis.

The latest launch of GenomOncology's Pathology Workbench allows for the parallel processing of samples via the annotation pipeline, improving sample annotation time by 80 percent. For instance, one TSO500 NovaSeq run of 150 samples can be entirely processed in 3 hours. Acknowledging insufficient standardization in how non-SNV calls are represented by NGS pipelines, this new launch also supports custom parsing of copy number alterations, fusions, MSI, and TMB results from any types of source files, and improved user interfaces for quality control review and interpretation for these types of biomarkers.

"The updates to GenomOncology's Pathology Workbench are designed to help labs and institutions working to scale their test volume and panel sizes, as well as introduce CNV and structural variant results by NGS. With the GO Pathology Workbench, users are provided with a workflow and clinical interpretation knowledge base that streamlines the process, quickly turning around reports that provide relevant clinical trial and therapy recommendations for patients," stated Matt Stachowiak, PhD, Director of Product Management.

Weekly Brief